Peptide use is growing, often through unregulated sellers and informal markets. STAT argues the FDA should consider a third path instead of a ban or laissez-faire approach.
Americans are using peptide compounds in large and growing numbers, and many are getting them from unregulated online sellers and informal markets. These products are promoted for recovery, sleep, performance, metabolic health and longevity, but they are often used without medical supervision, reliable quality controls or accurate dosing information. That makes the current landscape a mainstream reality, even if it is one regulators may want to prevent. With Kyle Diamantas now leading the Food and Drug Administration as acting commissioner, the agency has an opportunity to respond. Instead of leaving peptides to unrestricted gray-market access or turning to a blanket crackdown that could push use further underground, the FDA could pursue a third approach. The details of that path were not reported in the source.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.